🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

From the newest issue— Allosteric Regulation of Switch-II Domain Controls #KRAS Oncogenicity, by Simanshu Dhirendra, @FredNatLab, Kevin Haigis Lab et al. bit.ly/3tgS8kZ Dana-Farber News

Happy to host Simanshu Dhirendra, an expert on RAS proteins @FredNatLab. His seminar is at 006 Psychology from 4:10 pm on 10/5 (Thu). #cancer Ohio State Chemistry and Biochemistry The James chemistry.osu.edu/events/dr.-dhi…

In this issue, we review the SHOC2-MRAS-PP1C (SMP) complex assembly, the substitution of MRAS by the canonical RAS proteins, and explore potential therapeutic approaches for targeting the SMP complex in RAS/RAF-driven cancers and RASopathies. febs.onlinelibrary.wiley.com/doi/epdf/10.11…

Our latest study in Science Advances delves into KRAS4a, an overlooked splice variant, alongside KRAS4b. We uncover their unique structural and functional traits, emphasizing how HVR variations modulate interactions with PDEdelta, RAF, and PI3K. #KRAS4a science.org/doi/10.1126/sc…

The three-part New Drugs on the Horizon Series at the AACR Annual Meeting 2024 wrapped up this morning. A total of 12 first-time disclosures were presented. bit.ly/3J8AmVM #AACR24

Check out our latest review regarding the biology of RAS GTPase effectors! It was fun to write this with Alessandro Mozzarelli and Simanshu Dhirendra for Molecular Cell. Bottom line: lots of knowledge on these proteins, but many questions that remain to be answered. cell.com/molecular-cell…

Online Now: Functional and structural insights into RAS effector proteins dlvr.it/T9kDnf

Our structural-guided insights contributed to the design of BBO-8520, a first-in-class dual inhibitor targeting both GTP-bound (ON) and GDP-bound (OFF) KRAS G12C. Excited to see this work now published in Cancer Discovery! @FredNatLab BridgeBio Pharma